000166049 001__ 166049
000166049 005__ 20240229123219.0
000166049 0247_ $$2doi$$a10.1093/rap/rkaa048
000166049 0247_ $$2pmid$$apmid:33241174
000166049 0247_ $$2pmc$$apmc:PMC7673201
000166049 037__ $$aDKFZ-2020-02588
000166049 041__ $$aeng
000166049 082__ $$a610
000166049 1001_ $$0P:(DE-He78)9af7dea9c075a972fcfa22b583471dae$$aThomsen, Hauke$$b0$$eFirst author
000166049 245__ $$aFamilial associations for rheumatoid autoimmune diseases.
000166049 260__ $$aOxford$$bOxford University Press$$c2020
000166049 3367_ $$2DRIVER$$aarticle
000166049 3367_ $$2DataCite$$aOutput Types/Journal article
000166049 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1683890384_20086
000166049 3367_ $$2BibTeX$$aARTICLE
000166049 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000166049 3367_ $$00$$2EndNote$$aJournal Article
000166049 500__ $$a#EA:C050#LA:C050#LA:C020#
000166049 520__ $$aPrevious studies have shown a familial component in RA and in some other rheumatic autoimmune diseases (RAIDs), but because of the different study designs the risk estimates for familial risks differ extensively. The objective of this study is to identify familial components for RAIDs.We collected data on patients diagnosed in Swedish hospitals with RA, AS, PM/DM, SS, SLE and SSc (and scleroderma) and calculated familial standardized incidence ratios (SIRs) for each of these (concordant) and between them (discordant).The combined number of RAID patients in the offspring population (for whom SIRs were calculated) was 71 544, and in the whole population the number was 152 714, accounting for 19.8% of all autoimmune diseases in Sweden. AS showed the highest concordant familial risk of 18.42, followed by SLE (14.04), SS (8.63), SSc (4.50), PM/DM (4.03) and RA (3.03). There was no sex difference in SIRs. Risks for AS and SLE were 80.28 and 19.53 for persons whose parents and siblings were affected. Discordant risks were far lower than concordant risks, but they were significant for RA with all the other five RAIDs, for SLE and SSc with four RAIDs, for AS and SS with three RAIDs and for PM/DM with two RAIDs, attesting to extensive polyautoimmunity between RAIDs.The derived familial risks in this nationwide family study on medically diagnosed RAID are compatible with emerging evidence on the polygenic background of these complex diseases. Novel genetic pathways offer new therapeutic targets that alleviate disease onset optimally in high-risk familial patients and others.
000166049 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000166049 588__ $$aDataset connected to CrossRef, PubMed,
000166049 7001_ $$aLi, Xinjun$$b1
000166049 7001_ $$aSundquist, Kristina$$b2
000166049 7001_ $$aSundquist, Jan$$b3
000166049 7001_ $$0P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aFörsti, Asta$$b4
000166049 7001_ $$0P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aHemminki, Kari$$b5$$eLast author
000166049 773__ $$0PERI:(DE-600)2899298-2$$a10.1093/rap/rkaa048$$gVol. 4, no. 2, p. rkaa048$$n2$$prkaa048$$tRheumatology advances in practice$$v4$$x2514-1775$$y2020
000166049 909CO $$ooai:inrepo02.dkfz.de:166049$$pVDB
000166049 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9af7dea9c075a972fcfa22b583471dae$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000166049 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000166049 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000166049 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000166049 9141_ $$y2020
000166049 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-09-02
000166049 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-09-02
000166049 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-09-02
000166049 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-09-02
000166049 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-09-02
000166049 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2020-09-02
000166049 915__ $$0LIC:(DE-HGF)CCBYNCNV$$2V:(DE-HGF)$$aCreative Commons Attribution-NonCommercial CC BY-NC (No Version)$$bDOAJ$$d2020-09-02
000166049 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-09-02
000166049 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2020-09-02
000166049 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-09-02
000166049 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2020-09-02
000166049 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-09-02
000166049 9201_ $$0I:(DE-He78)C050-20160331$$kC050$$lMolekular-Genetische Epidemiologie$$x0
000166049 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x1
000166049 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000166049 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x3
000166049 980__ $$ajournal
000166049 980__ $$aVDB
000166049 980__ $$aI:(DE-He78)C050-20160331
000166049 980__ $$aI:(DE-He78)B062-20160331
000166049 980__ $$aI:(DE-He78)HD01-20160331
000166049 980__ $$aI:(DE-He78)C020-20160331
000166049 980__ $$aUNRESTRICTED